Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer.

C S Foster

    Ophthalmology
    |October 1, 1985
    PubMed
    Summary

    Cytotoxic immunosuppressive therapy, using methotrexate or cyclophosphamide, effectively treated progressive bilateral Mooren's ulcer in most patients. This approach arrested the destructive inflammatory process, preserving ocular function and anatomy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer.

    British journal of cancer·2014
    Same author

    Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.

    Prostate cancer and prostatic diseases·2012
    Same author

    Atopic keratoconjunctivitis.

    Ocular immunology and inflammation·2012
    Same author

    Splice variant PRKC-ζ(-PrC) is a novel biomarker of human prostate cancer.

    British journal of cancer·2012
    Same author

    Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

    British journal of cancer·2012
    Same author

    Difluprednate for inflammatory eye disorders.

    Drugs of today (Barcelona, Spain : 1998)·2011

    Area of Science:

    • Ophthalmology
    • Immunosuppression
    • Rheumatology

    Background:

    • Mooren's ulcer is a rare, progressive, and destructive inflammatory condition affecting the peripheral cornea.
    • Conventional ocular and systemic therapies often fail to manage bilateral progressive cases.
    • This condition can lead to significant vision loss and ocular morbidity.

    Purpose of the Study:

    • To evaluate the efficacy of cytotoxic immunosuppressive therapy in patients with progressive bilateral Mooren's ulcer.
    • To determine if methotrexate or cyclophosphamide can arrest the inflammatory process and preserve ocular function.
    • To assess the safety and long-term outcomes of this treatment approach.

    Main Methods:

    • Nine patients with progressive bilateral Mooren's ulcer were treated.
    • Treatment involved immunosuppressive doses of methotrexate or cyclophosphamide.
    • Patients were monitored for disease progression, ocular anatomy, and function for 6 to 24 months.

    Main Results:

    • Eight out of nine patients achieved arrest of the inflammatory process.
    • Ocular anatomy and function were preserved in the successfully treated patients.
    • One patient with inadequate therapy and follow-up experienced complete destruction of both eyes.

    Conclusions:

    • Cytotoxic immunosuppressive therapy with methotrexate or cyclophosphamide is a viable treatment option for bilateral progressive Mooren's ulcer.
    • Proper dosing and consistent follow-up are crucial for successful outcomes.
    • This therapy can effectively halt corneal destruction and preserve vision in most cases.

    Related Experiment Videos